<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00602693</url>
  </required_header>
  <id_info>
    <org_study_id>2007LS022</org_study_id>
    <secondary_id>MT2006-01</secondary_id>
    <secondary_id>0701M00303</secondary_id>
    <nct_id>NCT00602693</nct_id>
  </id_info>
  <brief_title>T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer</brief_title>
  <official_title>Phase I Study of Infusion of Umbilical Cord Blood (UCB) Derived CD25+CD4+ T-Regulatory (Treg) Cells After Nonmyeloablative Cord Blood Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy, such as fludarabine and cyclophosphamide, and total-body
      irradiation before a donor umbilical cord blood transplant helps stop the patient's immune
      system from rejecting the donor's stem cells. The donated stem cells may replace the
      patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor
      effect). Giving an infusion of the donor's T-regulatory cells after the transplant may
      decrease this effect. Sometimes the transplanted cells from a donor can also make an immune
      response against the body's normal cells. However, the donor immune system may also react
      against the recipient's tissues (graft-versus-host disease).

      PURPOSE: This phase I trial is studying the side effects and best dose of donor T-regulatory
      cells after an umbilical cord blood transplant in treating patients with advanced hematologic
      cancer or other disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the maximum tolerated dose (MTD) of umbilical cord blood (UCB)-derived
           T-regulatory (Treg) cells.

      Secondary

        -  Estimate the proportion of patients with detectable circulating Treg cells at 0, 1, 3,
           7, and 14 days after infusion.

        -  Estimate the risk of grades II-IV and III-IV acute graft versus host disease (GVHD) at
           day +100 with the infusion of Treg cells.

        -  Estimate the proportion of patients with sustained donor engraftment.

        -  Estimate the proportion of patients with double chimerism at 6 months and 1 year.

        -  Determine the speed and cumulative incidence of neutrophil recovery by day 42 and
           platelet recovery by 6 months after UCB transplantation.

        -  Estimate the risk of chronic GVHD at 1 year.

        -  Estimate the probability of disease-free survival at 100 days and 1 year.

        -  Estimate the risk of fungal and viral infections at 1 year

        -  Estimate the risk of relapse at 1 year

        -  Characterize the pattern of immune cell recovery over 1 year

      OUTLINE: This is a dose-escalation study of umbilical cord blood (UCB)-derived T-regulatory
      (Treg) cells. Patients receive nonmyeloablative UCB transplantation and post-transplant
      immunosuppression as in protocol UMN-2005LS036 (without antithymocyte globulin during
      conditioning regimen).

        -  Nonmyeloablative conditioning and UCB transplantation: Patients receive allopurinol on
           days -7 to day 0, fludarabine phosphate intravenously (IV) over 1 hour on days -6 to -2
           and cyclophosphamide IV over 2 hours on day -6; undergo total-body irradiation (TBI)
           once on day -1; and undergo UCB transplantation on day 0.

        -  Immunosuppression therapy: Beginning on day -3 and continuing until day +100, patients
           receive sirolimus intravenously (IV) with 8-12 mg oral loading dose followed by a single
           dose of 4mg/day with a target serum concentration of 3-12 mg/mL with a taper until day
           +180. Patients also receive mycophenolate mofetil IV or orally every 8 hours on days -3
           to +30.

        -  Radiation therapy: total body irradiation is administered on Day -1 of 200 cGy.

        -  UCB Treg cell infusion: Patients receive escalating doses of UCB-derived CD4+ CD25+ Treg
           cells IV on day +1 (and Day +15 for dose level 5 only) until the maximum tolerated dose
           is obtained.

      After completion of study treatment, patients are followed at day 180, 360, and 720.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 23, 2007</start_date>
  <completion_date type="Actual">April 16, 2015</completion_date>
  <primary_completion_date type="Actual">September 25, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>48 Hours</time_frame>
    <description>Nine dose levels of CD4+CD25+ Treg are scheduled with the doses being 1, 3, 10, 30, 30+30, 100, 300, 1000, and 3000 x 10^5 Treg/kg recipient body weight. The dose escalation will proceed in cohorts of one patient until the first dose limiting toxicity (DLT) is observed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with detectable Treg cells</measure>
    <time_frame>Days 0, +1, +3, +7, and +14 after Treg cell infusion</time_frame>
    <description>determined by polymerase chain reaction (PCR) and flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with grade II-IV and grade III-IV acute graft versus host disease (GVHD)</measure>
    <time_frame>Day 100</time_frame>
    <description>Patients will be assessed weekly for GVHD between days 0 and 100 after transplantation using standard criteria. Patients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level. Incidence of grades II-IV and grades III-IV GVHD by day 100 will be monitored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with sustained donor engraftment</measure>
    <time_frame>Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with double chimerism</measure>
    <time_frame>6 Months and 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neutrophil recovery after umbilical cord blood (UCB) transplantation</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Chronic Graft Versus Host Disease (GVHD)</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with disease-free survival</measure>
    <time_frame>Day 100 and 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Fungal and Viral Infections</measure>
    <time_frame>1 Year</time_frame>
    <description>Count of reported infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of platelet recovery after umbilical cord blood (UCB)</measure>
    <time_frame>6 Months After Transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Disease Relapse</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients with Immune Cell Recovery</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>UCB post-transplant Treg Cell Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Includes patients with high risk malignancy receiving allopurinol, fludarabine phosphate, cyclophosphamide, sirolimus, total body irradiation, double umbilical cord blood transplantation and Treg infusion cells after transplant. Patients will receive differing dose levels as they are entered and assigned to determine the maximum tolerated dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
    <description>Infusion of umbilical cord blood</description>
    <arm_group_label>UCB post-transplant Treg Cell Infusion</arm_group_label>
    <other_name>UCB transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Administration begins Day -7 through Day 0, tablet or powder prescribed on an individual basis.</description>
    <arm_group_label>UCB post-transplant Treg Cell Infusion</arm_group_label>
    <other_name>Zyloprim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>40 mg/m^2 intravenously over 1 hour on Days -6, -5, -4, -3, -2</description>
    <arm_group_label>UCB post-transplant Treg Cell Infusion</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>50 mg/kg intravenous over 2 hours on Day -6</description>
    <arm_group_label>UCB post-transplant Treg Cell Infusion</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total body irradiation</intervention_name>
    <description>200 cGy on Day -1</description>
    <arm_group_label>UCB post-transplant Treg Cell Infusion</arm_group_label>
    <other_name>radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Treg infusion</intervention_name>
    <description>Infusion of T regulatory cells on Day +1 (also Day +15 for Dose level 5 only). Dose escalation ranges include 1, 3, 10, 30, 100, 300 1000, and 300 x 10^5 Treg/kg.</description>
    <arm_group_label>UCB post-transplant Treg Cell Infusion</arm_group_label>
    <other_name>Treg cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Beginning on day -3 and continuing until day +100, patients receive sirolimus intravenously (IV) with 8-12 mg oral loading dose followed by a single dose of 4mg/day with a target serum concentration of 3-12 mg/mL with a taper until day +180.</description>
    <arm_group_label>UCB post-transplant Treg Cell Infusion</arm_group_label>
    <other_name>RapamuneÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 18 to 75 years old

          -  Eligible for and co-enrolled on protocol UMN-2005LS036, for treatment of any of the
             following advanced hematologic malignancies:

               -  Acute leukemias in complete remission (high risk CR1 or subsequent CR); chronic
                  myelogenous leukemia (except refractory blast crisis); myelodysplastic syndrome
                  with severe pancytopenia or complex cytogenetics, large-cell lymphoma, Hodgkin's
                  lymphoma and multiple myeloma, chronic lymphocytic leukemia/small lymphocytic
                  lymphoma, marginal zone b-cell lymphoma, follicular lymphoma, lymphoplasmacytic
                  lymphoma, mantle-cell lymphoma, prolymphocytic leukemia may be eligible after
                  initial therapy.

          -  Have three partially HLA matched umbilical cord blood (UCB) units (1-2 units for UCB
             transplantation per MT2005-02 and 1 unit for the Treg cell infusion.)

          -  Adequate organ function

        Exclusion Criteria:

          -  Patients not exposed to highly immunosuppressive single agent or multi-agent
             chemotherapy within 3 months, or an ablative preparative regimen for autologous
             hematopoietic stem cell transplant (HCT) within 1 year.

          -  Pregnancy or breastfeeding

          -  Current active serious infection

          -  Evidence of human immunodeficiency virus (HIV) or known HIV positive serology

          -  Patients with acute leukemia in morphologic relapse/persistent disease defined as &gt;5%
             blasts in a &gt; or = 15% cellular bone marrow or any % blasts if blasts have unique
             morphologic markers (e.g., Auer rods) or associated cytogenetic markers that allows
             morphologic relapse to be distinguished are not eligible.

          -  Chronic myelogenous leukemia in refractory blast crisis.

          -  Active central nervous system malignancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio G. Brunstein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margaret L. MacMillan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>January 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic myelogenous leukemia</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>advanced chronic lymphocytic leukemia</keyword>
  <keyword>small lymphocytic lymphoma</keyword>
  <keyword>B-cell lymphoma</keyword>
  <keyword>follicular lymphoma</keyword>
  <keyword>diffuse large cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>Hodgkin lymphoma</keyword>
  <keyword>multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

